Sara Bonstein - Jul 7, 2025 Form 4 Insider Report for INSMED Inc (INSM)

Role
Chief Financial Officer
Signature
/s/ Sara Bonstein, by Michael A. Smith as Attorney-in-fact
Stock symbol
INSM
Transactions as of
Jul 7, 2025
Transactions value $
-$4,320,687
Form type
4
Date filed
7/9/2025, 04:18 PM
Previous filing
Jun 25, 2025
Next filing
Jul 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bonstein Sara Chief Financial Officer 700 US HIGHWAY 202/206, BRIDGEWATER /s/ Sara Bonstein, by Michael A. Smith as Attorney-in-fact 2025-07-09 0001604019

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSM Common Stock Options Exercise $123K +6.24K +6.65% $19.74 100K Jul 7, 2025 Direct F1, F2
transaction INSM Common Stock Options Exercise $108K +4.36K +4.36% $24.70 104K Jul 7, 2025 Direct F1
transaction INSM Common Stock Options Exercise $623K +23.6K +22.55% $26.43 128K Jul 7, 2025 Direct F1
transaction INSM Common Stock Options Exercise $363K +13.7K +10.71% $26.46 142K Jul 7, 2025 Direct F1
transaction INSM Common Stock Sale -$3.4M -35.6K -25.1% $95.66 106K Jul 7, 2025 Direct F1, F3
transaction INSM Common Stock Sale -$2.13M -22.2K -20.89% $96.19 84K Jul 7, 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSM Stock Option (right to buy) Options Exercise $0 -6.24K -24.85% $0.00 18.9K Jul 7, 2025 Common Stock 6.24K $19.74 Direct F1, F5
transaction INSM Stock Option (right to buy) Options Exercise $0 -4.36K -100% $0.00 0 Jul 7, 2025 Common Stock 4.36K $24.70 Direct F1, F6
transaction INSM Stock Option (right to buy) Options Exercise $0 -23.6K -60% $0.00 15.7K Jul 7, 2025 Common Stock 23.6K $26.43 Direct F1, F5
transaction INSM Stock Option (right to buy) Options Exercise $0 -13.7K -53.29% $0.00 12K Jul 7, 2025 Common Stock 13.7K $26.46 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 5, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Includes 357 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
F3 This is the weighted average sales price representing 35,583 shares sold at prices ranging from $95.01 to $96.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4 This is the weighted average sales price representing 22,181 shares sold at prices ranging from $96.01 to $96.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F5 The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
F6 The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.